Wound Clinical Trial
Official title:
Assessment of Wound Healing, Cooling Efficacy and Local Tolerability of a Wound Care Hydrogel With Intraindividual Comparison Using an Abrasive Wound Model in a Single-center, Randomized, Investigatorblind Clinical Investigation.
NCT number | NCT06309446 |
Other study ID # | 381001BS |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 14, 2020 |
Est. completion date | July 2, 2020 |
Verified date | March 2024 |
Source | Oystershell NV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Test the wound healing properties of the product as well as the cooling effect and tolerability of a wound care gel.
Status | Completed |
Enrollment | 33 |
Est. completion date | July 2, 2020 |
Est. primary completion date | February 19, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women aged 18 years or older; - Healthy skin on the volar forearms; - The physical examination of the skin must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical investigation; - Female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices (IUDs), sexual abstinence or vasectomized partner; - Urine pregnancy test negative for all females; - Written informed consent obtained. Exclusion Criteria: - Acne, suntan, eczema, scars, excessive hair, acute skin infection or skin disease, hyper or hypopigmentation or tattoos in the test fields; - Dark-skinned persons (Fitzpatrick skin types IV-VI); - Pregnancy or planned pregnancy or nursing; - Symptoms of a clinically significant illness that may influence the outcome of the investigation in the 4 weeks before baseline and during the clinical investigation; - Participation in the treatment phase in another clinical investigation or clinical trial within the last 4 weeks prior to the baseline visit of this clinical investigation and during the conduct of this investigation; - Known hypersensitivity or known allergic reactions to components of the MD or the protective standard wound plaster used; - Treatment with systemic medications or medications acting locally in the test field areas which might counter or influence the investigation aim within 2 weeks before the baseline visit (e.g. antihistamines or glucocorticosteroids) and during the conduct of this investigation; - Subjects who have taken any anticoagulant medication, within 3 weeks prior to Day 1, or platelet aggregation inhibitors within 10 days prior to Day 1 or with a history of hemophilia or any other illness influencing the subject's coagulation system. - Subjects with diabetes mellitus or presence or history of psoriasis, atopic dermatitis, lichen ruber planus, impaired wound healing or keloid development; - Contraindications according to the package leaflet/instructions of use (Hansaplast Sensitive); - If in the opinion of the investigator or physician performing the initial examination the subject should not participate in the clinical investigation, e.g. due to probable noncompliance or inability to understand the investigation and adequately given informed consent; - Subjects not willing to adhere to trial restrictions, amongst others sauna, solarium are not allowed during the clinical investigation; - Close affiliation with the investigator (e.g. a close relative) or persons working at bioskin GmbH or subject is an employee of the sponsor; - Subject with a disposition to develop hypertrophic scarring, keloids or wound healing disorders; - Evidence of drug or alcohol abuse; - Subject is institutionalized because of legal or regulatory order. |
Country | Name | City | State |
---|---|---|---|
Germany | Bioskin GmbH | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Oystershell NV | Bioskin GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wound healing efficacy (clinical) | Clinical assessment of wound healing efficacy performed by investigator (6-point- reepithelialization score).
0 = 0% healing = 1-25% re-epithelialization = 26-50% re-epithelialization = 51-75% re-epithelialization = over 75% but not complete re-epithelialization = 100% complete healing |
Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Primary | Wound healing efficacy (global) | Global assessment of wound healing efficacy performed by investigator (5-point score).
0 = very good = good = acceptable = poor = very poor |
Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Primary | Cooling properties | Subjective assessment of cooling properties performed by subject by completing a visual analogue scale on Day 1 immediately after application of the Medical Device (MD).The cooling effect in the two test fields will be assessed by the subject by means of a visual analogue scale (VAS) of 100 mm length, ranging from 0 (no cooling) to 100 (extremely cooling) on Day 1, 20 ±5 seconds after application of the MD (but prior to application of the protective wound plaster). | Day 1 | |
Secondary | Local tolerability (clinical) | Clinical assessment of local tolerability performed by investigator (5-point-erythemascore).
0 = no reaction = slight uniform or spotty erythema or slight diffuse, partial or follicular erythema = clear, sharply demarcated erythema = severe erythema with infiltrate = severe erythema with infiltrate and/or epidermal defect (blisters, blebs, erosions) |
Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Local tolerability (global) | Global assessment of local tolerability performed by subject and investigator (5-point score). 0 = very good
= good = acceptable = poor = very poor |
Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Signs of infection | Assessment of signs of infection, considering the following parameters: erythema, pain, malodor, delayed wound healing, excessive exudate, and heat, by investigator (closed question: YES/NO). | Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Time until 100% healing | Time until 100% healing, defined as first day after wound induction with reepithelialization score of 5 (5 = 100% complete healing). | Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Time until 75% healing | Time until over 75% healing, defined as first day after wound induction with reepithelialization score of 4 or 5 (4 = over 75% but not complete re-epithelialization; 5 = 100% complete healing). | Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Presence of crusts | Presence of crusts (Yes/No) | Day 2, Day 6, Day 8, Day 10 & Day 12 | |
Secondary | Questionnaire on product performance | Questionnaire on product performance (filled by subjects) on Day 12 (12 closed questions) | Day 12 | |
Secondary | Cosmetic outcome/acceptance | The cosmetic outcome/acceptance will be assessed by the investigator and the subject by means of a visual analogue scale (VAS) of 100 mm length, ranging from 0 (poor) to 10 (excellent) on Day 31±2 for each of the two test fields. | Day 31 | |
Secondary | Photographic documentation of the wound - visual of the wound to support previous outcomes. | High-quality photographic documentation of the test sites on Days 1, 4, 6, 8, 10, 12 and 31 sufficient time (not earlier than 30 minutes but not later than 60 minutes) after removal of patches and product residues for any removal related erythema to subside. | Day 1, Day 4, Day 6, Day 8, Day 10, Day 12 & Day 31 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03649308 -
Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting
|
N/A | |
Recruiting |
NCT03674749 -
The Effects of Meditation and Hyperbaric Oxygen Therapy on Chronic Wounds
|
N/A | |
Completed |
NCT06464250 -
The Effect of Bundle Approach on Foot Care Behaviors and Diabetic Wound Healing in Patients
|
N/A | |
Withdrawn |
NCT03909503 -
A Case Series Evaluating a Collagen Wound Dressing to Treat Wounds
|
N/A | |
Completed |
NCT05297721 -
Nurses' Level of Knowledge on Skin Tears: A Cross-Sectional Study
|
||
Recruiting |
NCT03386175 -
Efficiency of Negative Pression Therapy With Instillation in the Debridement of Wound
|
||
Active, not recruiting |
NCT04701632 -
Prevalence and Variables Associated With Depression in Subjects With Chronic Wounds Using PHQ-9 as a Screening Tool
|
||
Completed |
NCT05618496 -
Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients
|
N/A | |
Not yet recruiting |
NCT03640871 -
HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer
|
N/A | |
Completed |
NCT02399722 -
Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone
|
N/A | |
Completed |
NCT04507724 -
The Use of Biochemical Analyzes to Monitor the Development of Wounds
|
||
Recruiting |
NCT05556954 -
Diabetic Foot Ulcers Microbiome and Pathogen Identification
|
||
Completed |
NCT03938584 -
The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients
|
N/A | |
Terminated |
NCT03723603 -
An Evaluation of a Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds
|
N/A | |
Completed |
NCT03754426 -
A Prospective, Pilot Evaluation of Device Equivalence
|
||
Recruiting |
NCT02643680 -
Clinical Study of Biocellulose Wound Dressing Containing Silk Sericin and PHMB for STSG Donor Sites
|
Phase 2 | |
Recruiting |
NCT01913132 -
PICO Above Incisions After Vascular Surgery
|
N/A | |
Recruiting |
NCT01347489 -
Cronic Pressure Wounds and Relation With Gender
|
N/A | |
Recruiting |
NCT04621825 -
Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam
|
N/A | |
Withdrawn |
NCT03723577 -
An Evaluation of a Fibrillar Collagen Dressing to Treat Chronic, Stalled Lower-extremity Wounds
|
N/A |